data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
SPY
––%
QQQ
––%
BTC/USD
––%
DIA
––%
GLD
––%
TLT
––%
GT Biopharma
(NASDAQ:GTBP)
$1.685
0.085[5.31%]
At close: Nov 30(Delayed 15-Minutes)
Get Real Time Here
$1.52
-0.1650[-9.79%]
After Hours: 6:47PM EDT
Day Range1.5 - 1.6952 Wk Range1.46 - 4.59Open / Close1.57 / -Float / Outstanding31.2M / 32.6M
Vol / Avg.153K / 76.4KMkt Cap54.9MP/E-50d Avg. Price1.85
Div / Yield-Payout Ratio-Total Float31.2MEPS-0.22

GT Biopharma Stock (NASDAQ:GTBP), Quotes and News Summary

GT Biopharma Stock (NASDAQ: GTBP) stock price, news, charts, stock research, profile.

Day Range1.5 - 1.6952 Wk Range1.46 - 4.59Open / Close1.57 / -Float / Outstanding31.2M / 32.6M
Vol / Avg.153K / 76.4KMkt Cap54.9MP/E-50d Avg. Price1.85
Div / Yield-Payout Ratio-Total Float31.2MEPS-0.22
Globe Newswire - Nov 10, 2022, 3:15PM
Globe Newswire - Nov 3, 2022, 9:00AM
Globe Newswire - Oct 31, 2022, 5:15PM
Newsfile - Oct 25, 2022, 2:44PM
Globe Newswire - Oct 6, 2022, 8:18AM
Globe Newswire - Oct 4, 2022, 4:10PM
Globe Newswire - Sep 12, 2022, 9:34AM
Globe Newswire - Sep 8, 2022, 7:30AM
Globe Newswire - Aug 30, 2022, 6:00PM
Globe Newswire - Aug 11, 2022, 9:35AM
Globe Newswire - Jun 10, 2022, 8:00AM
Globe Newswire - May 16, 2022, 8:01AM
Globe Newswire - May 12, 2022, 8:00AM
Globe Newswire - Apr 11, 2022, 7:30AM
PRNewswire - Mar 28, 2022, 4:15PM
PRNewswire - Mar 21, 2022, 7:30AM
PRNewswire - Mar 9, 2022, 4:24PM
PRNewswire - Mar 3, 2022, 7:30AM
PRNewswire - Feb 24, 2022, 7:30AM
PRNewswire - Feb 18, 2022, 7:30AM
PRNewswire - Jan 20, 2022, 7:30AM
PRNewswire - Jan 6, 2022, 4:30PM
PRNewswire - Dec 8, 2021, 7:30AM
InvestorsObserver - 1 hour ago
TipRanks - Nov 18, 2022, 6:30AM
InvestorsObserver - Oct 28, 2022, 3:16PM
InvestorsObserver - Oct 12, 2022, 3:18PM
InvestorsObserver - Sep 30, 2022, 3:05PM
TipRanks - Sep 13, 2022, 6:20AM
InvestorsObserver - Sep 8, 2022, 2:54PM
InvestorsObserver - Aug 26, 2022, 2:26PM
TipRanks - Aug 17, 2022, 6:30AM
InvestorsObserver - Jul 13, 2022, 2:45PM
InvestorsObserver - Jun 28, 2022, 3:18PM
InvestorsObserver - May 19, 2022, 2:42PM
TipRanks - May 19, 2022, 11:45AM
TipRanks - May 17, 2022, 6:25AM
InvestorsObserver - May 13, 2022, 2:49PM
InvestorsObserver - May 10, 2022, 2:03PM
InvestorsObserver - Apr 27, 2022, 2:15PM
InvestorsObserver - Apr 26, 2022, 1:17PM
InvestorsObserver - Apr 25, 2022, 1:24PM
InvestorsObserver - Apr 21, 2022, 2:23PM
InvestorsObserver - Apr 19, 2022, 3:17PM
InvestorsObserver - Apr 13, 2022, 2:56PM
TipRanks - Apr 12, 2022, 6:26AM
InvestorsObserver - Apr 11, 2022, 2:04PM
InvestorsObserver - Apr 1, 2022, 3:28PM
TipRanks - Mar 30, 2022, 8:55PM
InvestorsObserver - Mar 30, 2022, 2:00PM
InvestorsObserver - Mar 24, 2022, 1:45PM
InvestorsObserver - Mar 22, 2022, 12:54PM
InvestorsObserver - Mar 18, 2022, 3:04PM
TipRanks - Mar 11, 2022, 6:28AM
TipRanks - Mar 11, 2022, 2:45AM
InvestorsObserver - Mar 3, 2022, 1:58PM
InvestorsObserver - Mar 1, 2022, 2:29PM
InvestorsObserver - Feb 25, 2022, 12:51PM
Sector: Health Care.Industry: Biotechnology
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Read More

Earnings

see more
Q3 2022Est.ActualSurprise
EPS-0.110-0.220 -0.1100
REV0
Q2 2022Est.ActualSurprise
EPS-0.170-0.100 0.0700
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy GT Biopharma (GTBP) stock?

A

You can purchase shares of GT Biopharma (NASDAQ: GTBP) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are GT Biopharma's (GTBP) competitors?

Q

What is the target price for GT Biopharma (GTBP) stock?

A

The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by HC Wainwright & Co. on Tuesday, September 13, 2022. The analyst firm set a price target for 5.00 expecting GTBP to rise to within 12 months (a possible 196.74% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for GT Biopharma (GTBP)?

A

The stock price for GT Biopharma (NASDAQ: GTBP) is $1.685 last updated Today at November 30, 2022, 8:48 PM UTC.

Q

Does GT Biopharma (GTBP) pay a dividend?

A

There are no upcoming dividends for GT Biopharma.

Q

When is GT Biopharma (NASDAQ:GTBP) reporting earnings?

A

GT Biopharma’s Q3 earnings are confirmed for Monday, October 31, 2022.

Q

Is GT Biopharma (GTBP) going to split?

A

There is no upcoming split for GT Biopharma.

Q

What sector and industry does GT Biopharma (GTBP) operate in?

A

GT Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.